Please wait...
Free, same-day prescription delivery to your doorstep is available in your area.
Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
USARx offers the following ways to purchase this medication. Choose the Best option for you!
For all patients taking Panzyga (immune globulin injection (IV)):
Children:
This is not a list of all drugs or health problems that interact with Panzyga (immune globulin injection (IV)).
Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take Panzyga (immune globulin injection (IV)) with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.
Use Panzyga (immune globulin injection (IV)) as ordered by your doctor. Read all information given to you. Follow all instructions closely.
What do I do if I miss a dose?
WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:
All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:
These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.
You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch.
If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
Other brands: Privigen, Octagam, Panzyga, Gammaplex, ... +5 more
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/27/2021.
Source: Drugs.com Panzyga (www.drugs.com/cdi/panzyga-immune-globulin-injection-iv.html).
Applies to immune globulin intravenous: intravenous solution
Intravenous route (Solution)
Warning: Thrombosis, Renal Dysfunction, and Acute Renal FailureThrombosis may occur with immune globulin intravenous (IGIV) products, including immune globulin-ifas. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Immune globulin-ifas does not contain sucrose.For patients at risk of thrombosis, renal dysfunction, or renal failure, administer immune globulin-ifas at the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Along with its needed effects, immune globulin intravenous may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking immune globulin intravenous:
More common
Incidence not known
Some side effects of immune globulin intravenous may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
Incidence not known
For Healthcare Professionals
Applies to immune globulin intravenous: intravenous powder for injection, intravenous solution
GeneralThe most common adverse events were headache, cough, fatigue, infusion site reaction, nausea, urticaria, sinusitis, blood pressure increased, diarrhea, dizziness, and lethargy.
RespiratoryVery common (10% or more): Cough increased (54%), rhinitis (51%), pharyngitis (41%), asthma (29%), upper respiratory tract infection (25%), cough (22%), bronchitis (19%), epistaxis (10.5%)
Common (1% to 10%): Sinusitis, pharyngolaryngeal pain, pharyngitis, nasal congestion
Uncommon (0.1% to 1%): Bronchospasm
Frequency not reported: Dyspnea, wheezing
Postmarketing reports: Apnea, acute respiratory distress syndrome (ARDS), transfusion associated lung injury (TRALI), cyanosis, hypoxemia, pulmonary edema, bronchospasm, pulmonary embolism, hyperventilation, hypoxia, throat tightness, respiratory failure
CardiovascularVery common (10% or more): Hypotension (25%), tachycardia (25%), diastolic hypertension (21%)
Common (1% to 10%): Blood pressure increased, blood pressure diastolic decreased, palpitations
Uncommon (0.1% to 1%): Tachycardia, hypertension, blood pressure systolic decreased, blood pressure systolic increased, blood pressure fluctuation
Frequency not reported: Myocardial infarction
Postmarketing reports: Cardiac arrest, thromboembolism, vascular collapse, changes in blood pressure, flushing, cyanosis, bradycardia, thrombophlebitis, pallor vena cava thrombosis, arterial thrombosis, deep vein thrombosis
Nervous systemVery common (10% or more): Headache (64.9%)
Common (1% to 10%): Dizziness, lethargy, migraine, vertigo, sensory disturbance
Uncommon (0.1% to 1%): Tinnitus, tremor, dysgeusia
Frequency not reported: Aseptic meningitis, death from cerebrovascular hemorrhage, sleepiness
Postmarketing reports: Coma, loss of consciousness, seizures, photophobia, cerebrovascular accident, transient ischemic attack, convulsion, paresthesia, syncope, dysesthesia
GastrointestinalVery common (10% or more): Diarrhea (28%), nausea (22.2%)
Common (1% to 10%): Vomiting, upper abdominal pain, stomach discomfort
Uncommon (0.1% to 1%): Abdominal distension, flatulence
Frequency not reported: Gingival bleeding
Postmarketing reports: Abdominal pain, dyspepsia
OtherVery common (10% or more): Fatigue (38%), fever/pyrexia (38.6%), pain (25.5%), ear pain (18%), chills (19.4%), asthenia (10%)
Common (1% to 10%): Influenza-like illness, blood lactate dehydrogenase increased
Uncommon (0.1% to 1%): Hot flush, feeling jittery
Frequency not reported: Increased body temperature
Postmarketing reports: Rigors, chest pain/discomfort
HepaticVery common (10% or more): Transient borderline elevation in liver enzyme (13%), blood unconjugated bilirubin increased (10.5%)
Common (1% to 10%): Blood conjugated bilirubin increased, blood total bilirubin increased, hyperbilirubinemia, alanine aminotransferase increased, aspartate aminotransferase increased, hepatic enzymes increased
Postmarketing reports: Hepatic dysfunction, jaundice, non-infectious hepatitis
HematologicVery common (10% or more): Anemia (10.5%)
Common (1% to 10%): Hematocrit decreased, positive direct antiglobulin (Coombs/DAT) test
Uncommon (0.1% to 1%): Hemoglobin decreased, white blood cell count increased, anisocytosis
Frequency not reported: Autoimmune pure red cell aplasia, Coombs negative hypochromic anemia, hemolysis, decrease in hemoglobin level, active bleeding, anemia, thrombocytopenia, hemolytic anemia
Postmarketing reports: Pancytopenia, leukopenia, hemoglobinuria/hematuria/chromaturia, lymphadenopathy
LocalVery common (10% or more): Local pain and/or irritation (15.2%), injection site reaction (13%)
Common (1% to 10%): Infusion site pain
Uncommon (0.1% to 1%): Infusion site inflammation, injection site edema, injection site pruritus, injection site swelling, migration of implant
DermatologicCommon (1% to 10%): Hyperhidrosis, flushing, urticaria, pruritus, dermatitis exfoliative NOS, rash macular, eczema
Uncommon (0.1% to 1%): Exanthema, erythema multiforme, acne
Frequency not reported: Mild to moderate hives, itching, recurrence of chronic cellulitis
Postmarketing reports: Stevens-Johnson syndrome, epidermolysis, bullous dermatitis, rash, angioedema, dermatitis, erythema
HypersensitivityCommon (1% to 10%): Hypersensitivity
Postmarketing reports: Anaphylactic shock, anaphylactic/anaphylactoid reaction
MusculoskeletalVery common (10% or more): Backache (11.8%)
Common (1% to 10%): Joint pain/effusion, back pain, fibromyalgia, myalgia, arthralgia, muscle spasms, neck pain
Uncommon (0.1% to 1%): Leg cramps, musculoskeletal stiffness, pain in extremity
MetabolicCommon (1% to 10%): Fluid retention, dehydration
Uncommon (0.1% to 1%): Loss of appetite
Postmarketing reports: Fluid overload
RenalUncommon (0.1% to 1%): Urinary hemosiderin positive, proteinuria
Frequency not reported: Increase in serum creatinine
Postmarketing reports: Renal failure
PsychiatricUncommon (0.1% to 1%): Anxiety, agitation, insomnia
Postmarketing reports: Restlessness
OcularUncommon (0.1% to 1%): Vision blurred, conjunctivitis, maculopathy
Postmarketing reports: Photophobia, retinal vein thrombosis, eye pain, visual disturbance
ImmunologicFrequency not reported: Infection
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/27/2021.
Source: Drugs.com Panzyga (www.drugs.com/cdi/panzyga-immune-globulin-injection-iv.html).
December 16, 2020
March 1, 2021
February 15, 2021
March 1, 2021
February 1, 2021
January 31, 2021
Fact Checked
Health Integrity